Enliven Therapeutics, Inc. (ELVN)
46.97
+0.76
(+1.64%)
USD |
NASDAQ |
Oct 02, 16:00
46.97
0.00 (0.00%)
After-Hours: 20:00
Enliven Therapeutics Price to Book Value : 3.844 for Oct. 2, 2026
Price to Book Value Chart
Historical Price to Book Value Data
| Date | Value |
|---|---|
| October 02, 2026 | 3.844 |
| October 01, 2026 | 3.781 |
| September 30, 2026 | 3.751 |
| September 29, 2026 | 3.806 |
| September 28, 2026 | 3.765 |
| September 25, 2026 | 3.662 |
| September 24, 2026 | 3.696 |
| September 23, 2026 | 3.772 |
| September 22, 2026 | 3.944 |
| September 21, 2026 | 3.999 |
| September 18, 2026 | 4.047 |
| September 17, 2026 | 4.111 |
| September 16, 2026 | 4.020 |
| September 15, 2026 | 4.366 |
| September 14, 2026 | 4.454 |
| September 11, 2026 | 4.445 |
| September 10, 2026 | 4.601 |
| September 09, 2026 | 4.701 |
| September 08, 2026 | 4.858 |
| September 04, 2026 | 4.854 |
| September 03, 2026 | 4.881 |
| September 02, 2026 | 4.829 |
| September 01, 2026 | 4.735 |
| August 31, 2026 | 4.737 |
| August 28, 2026 | 4.735 |
| Date | Value |
|---|---|
| August 27, 2026 | 4.951 |
| August 26, 2026 | 4.981 |
| August 25, 2026 | 4.993 |
| August 24, 2026 | 5.004 |
| August 21, 2026 | 4.895 |
| August 20, 2026 | 4.822 |
| August 19, 2026 | 4.86 |
| August 18, 2026 | 4.916 |
| August 17, 2026 | 4.872 |
| August 14, 2026 | 4.813 |
| August 13, 2026 | 4.751 |
| August 12, 2026 | 4.740 |
| August 11, 2026 | 4.810 |
| August 10, 2026 | 4.862 |
| August 07, 2026 | 4.948 |
| August 06, 2026 | 4.932 |
| August 05, 2026 | 4.885 |
| August 04, 2026 | 5.001 |
| August 03, 2026 | 4.750 |
| July 31, 2026 | 4.485 |
| July 30, 2026 | 4.415 |
| July 29, 2026 | 4.335 |
| July 28, 2026 | 4.399 |
| July 27, 2026 | 4.315 |
| July 24, 2026 | 4.333 |
Price to Book Ratio Definition
Price to book value is a valuation ratio that is measured by stock price / book value per share. The book value is essentially the tangible accounting value of a firm compared to the market value that is shown.
Price to Book Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Price to Book Value Benchmarks
| Definium Therapeutics, Inc. | 5.470 |
| Cocrystal Pharma, Inc. | 15.12 |
| CNBX Pharmaceuticals, Inc. | -- |
| Arvinas, Inc. | 0.8607 |
| Fulcrum Therapeutics, Inc. | 0.906 |
Price to Book Value Related Metrics
| Price | 46.97 |
| Earnings Yield | -3.55% |
| Market Cap | 3.441B |